← All trials
NCT02778763
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 1, 2015
- Primary completion
- Jul 1, 2016
- Completion date
- Jul 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 23
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- BioLab 612 LLCLead sponsor
- St.-Petersburg State Budgetary Healtcare Institution City Clinical Oncological DispensaryOverall official - principal investigator
- Non-State Healtcare Institution Road Clinical Hospital of Open Joint Stock Company Russian RailwaysOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Russian Academy of Medical SciencesOverall official - principal investigator
- Cleveland BioLabsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.